Table 3 FGF23 and cardiac hypertrophy in CKD

 Gutierrez OM et al.

162 CKD

Incidence of LVH (%), FGF23 < 75 RU/ml; 7%, 75–150 RU/ml, 21%, > 150 RU/ml; 25%

[21]

 Faul C et al.

3070 CKD

Incidence of LVH (eccentric+concentric)%, FGF23 quarfile 1; 38%, quarfile 2; 45%, quartile 3; 54%, quarfile 4; 70%

[22]

 Hsu HJ et al.

124 hemodialysis

Serum FGF23 level is independently associated with LVH in hemodialysis patients

[118]

 Seifert Me et al.

31 CKD stage 3

The change in FGF23/klotho ratio was strongly correlated with changes in LV mass index.

[119]

 Sarmento-Dias M et al.

48 peritoneal dialysis

In multivariate adjusted analysis, FGF23was associated with LVMI (β = 0.298, p = 0.041),

[120]

 Javanovich A et al.

2255 elderly CKD

Higher FGF23 concentrations were associated with greater LVM in adjusted analyses (β = 6.71 [95% Cl 4.35–9.01] g per doubling of FGF23).

[121]

 Tanaka S. et al

903 CKD stage 1 to 5

The correlation between FGF23 and LVMI was significant among those with CKD stage G1/G2, G3a, and G4.

[122]

 Chue CD. et al

120 CKD stage 3

Sevelamer carbonate reduced FGF23 but failed to improve LV mass

[134]

 Maizel J et al.

CKD mice

Sevelamer reduced serum phosphate and LV hypertrophy but not FGF23.

[135]

 Yamazaki- Nakazawa A et al.

CKD rats

Lanthanum carbonate reduced LV weight but failed to decrease FGF23 levels.

[136]